Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01FX18
|
| gptkbp:brand |
Blenrep
|
| gptkbp:CASNumber |
2227365-92-4
|
| gptkbp:contains |
monomethyl auristatin F
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| https://www.w3.org/2000/01/rdf-schema#label |
belantamab mafodotin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:B-cell_maturation_antigen
|
| gptkbp:mechanismOfAction |
induces apoptosis in BCMA-expressing cells
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
blurred vision
thrombocytopenia keratopathy |
| gptkbp:target |
gptkb:BCMA
|
| gptkbp:UNII |
6QY1D9Y4F4
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:bfsParent |
gptkb:TNFRSF17
|
| gptkbp:bfsLayer |
7
|